Allena Pharmaceuticals, Inc. Gross Margin

Gross Margin of ALNA for past 10 years: annual, quarterly and twelve month trailing (TTM) including Gross Margin growth rates and interactive chart. Gross profit margin shows the percentage of revenue that exceeds a company's costs of goods sold. It illustrates how well a company is generating revenue from the costs involved in producing their products and services. The higher the margin, the more effective the company's management is in generating revenue for each dollar of cost. Gross profit margin is calculated by subtracting the cost of goods sold from total revenue for the period and dividing that number by revenue. If a company has $200 million in revenue and $80 million in cost of goods sold, the gross margin is 60%.


Highlights and Quick Summary

  • Gross Margin for the quarter ending December 31, 2021 was 0.0% (a NaN% decrease compared to previous quarter)
  • Year-over-year quarterly Gross Margin decreased by NaN%
  • Annual Gross Margin for 2021 was 0.0% (a NaN% decrease from previous year)
  • Annual Gross Margin for 2020 was 0.0% (a NaN% decrease from previous year)
  • Annual Gross Margin for 2019 was 0.0% (a NaN% decrease from previous year)
  • Twelve month Gross Margin ending December 31, 2021 was 0.0% (a NaN% decrease compared to previous quarter)
  • Twelve month trailing Gross Margin decreased by NaN% year-over-year
Trailing Gross Margin for the last four month:
31 Dec '21 30 Sep '21 30 Jun '21 31 Mar '21
0.0% 0.0% 0.0% 0.0%
Visit stockrow.com/ALNA for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Gross Margin of Allena Pharmaceuticals, Inc.

Most recent Gross Marginof ALNA including historical data for past 10 years.

Interactive Chart of Gross Margin of Allena Pharmaceuticals, Inc.

Allena Pharmaceuticals, Inc. Gross Margin for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 0.0% 0.0% 0.0% 0.0% 0.0%
2020 0.0% 0.0% 0.0% 0.0% 0.0%
2019 0.0% 0.0%
2018 0.0%
2017 0.0%
2016 0.0%

Business Profile of Allena Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.